Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Inclusion Criteria: * Participants with advanced, nonresectable, or recurrent solid tumor for which no alternative standard therapy or no effective therapy exists * Expansion-part 1 only: breast cancer with confirmed diagnosis, human epidermal growth factor (HER2) negative (immunohistochemistry \[IHC\] 0/1+, or fluorescence in situ hybridization \[FISH\] negative), prior chemotherapy of anthracycline and taxane (unless contraindicated), and up to 3 prior chemotherapy regimens to advanced or metastatic disease Expansion-part 2 only: nonresectable ACC with confirmed diagnosis and one or more prior chemotherapy regimens (unless contraindicated) Expansion-part 3, 4 and 5 only: nonresectable GC, EGC and SCLC with confirmed diagnosis and 2 or more prior chemotherapy regimens (unless contraindicated) (1 or more prior chemotherapy regimens for EGC participant who received combination therapy of platinum and taxane). Ex-part 6 only: breast cancer with confirmed diagnosis, HER2 negative (IHC 0/1+, or FISH negative) and without prior chemotherapy regimens to advanced or metastatic disease. Participants with triple-negative breast cancer (TNBC) who are PD-L1 negative as assessed by the site or who are medically determined by the investigator(s) to be ineligible for treatment with atezolizumab and other immune-checkpoint inhibitors will be included. * Life expectancy of greater than or equal to (\>=) 12 weeks * Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) of 0 to 1 *…